Rodney Rosalia, PhD - Zan Mitrev Clinic

Request an appointment

Request an appointment

00389 2 3091 484

Zan Mitrev's Team

Back to Doctors

Rodney Rosalia, PhD

Tumour immunology and vaccine development

Place of birth:

Curaçao

E-mail:

rodney.rosalia@zmc.mk

  • 2008 – 2013 PhD in tumour immunology and vaccine development, Leiden University Medical Center, Leiden, the Netherlands
  • 2004 – 2007 Sc. in Oncology, VU University, Amsterdam, The Netherlands.
  • 1999 – 2004 Sc. in Medical Science, Saxion University of professional education, Enschede, the Netherlands
  • 1993 – 1999 Higher General Secondary Education, the Radulphus College, Curaçao.

Advanced education & courses

  • A masterclass in Statistics and Research Methodology, European Association for Anaesthesiology, Katowice, Poland.
  • ICH-GCP, Whitehall training/TransCelerate BioPharma
  • Advanced course on Laboratory Animal Science, FELASA C, University of Zurich
  • Laboratory Animal Science, Faculty of biomedical science, Leiden University
  • Advanced Immunology, Faculty of Medicine, Leiden University
  • Trends in Immunology, Oncology Graduate School, VU University Amsterdam
  • Teaching Character and Creating Positive Classrooms, Relay Graduate School of Education
  • Teaching in English in a non-English speaking environment, Center for University Teaching and Learning of the University of Zurich
  • Supervising students – dealing with roles and relationships, Educational Development and Technology of the ETH Zurich
  • Scientific writing in English, VU University Amsterdam
  • Since Aug 2016  Scientific Officer, Quality Assurance Officer, Zan  Mitrev Clinic, Skopje, Macedonia
  • Aug 2016 – June 2017 Natural & Life Sciences teacher and scientific inquiry Coordinator, NOVA international schools, Skopje Macedonia
  • Sep 2013 – Feb 2016 Postdoctoral research associate, Department of  clinical immunology University Hospital Zurich, Switzerland
  • Sep 2008 – Apr 2013 PhD candidate, Division of Tumor Immunology, Leiden  University Medical Center, Leiden The Netherlands
  • Sep 2007 – Sep 2008 Graduate research assistant, cancer immunology laboratory, Institute for Molecular Genetics Prague, Czech Republic
  • Feb 2007 – Jul 2007 Research internship, immunotherapy laboratory VU, The Medical Center, Amsterdam, The Netherlands

Oral presentations

  • AROME ESO meeting, 2016, Macedonia
  • Joint Immunology meeting seminar, 2015, Switzerland
  • Joint cancer meeting seminar, 2015, Switzerland
  • Dutch Tumor Immunology Conference, 2011 & 2012, The Netherlands
  • 4th Wadden symposium “Novel strategies in immunotherapy of cancer,” 2011, The Netherlands.
  • FIGON “Dutch Medicine days” conference, 2011, The Netherlands.
  • EACR “9th International conference on progress in vaccination against Cancer” in 2009, Bulgaria

Poster presentations

  • Keystone Symposia Conference “Immunological Mechanisms of Vaccination,” 2012, Canada
  • EMBO 7th Antigen Processing and Presentation (APP) Workshop 2012, The Netherlands.
  • EACR 11th International conference on progress in vaccination against Cancer, 2011, Denmark.
  • 5th ENII EFIS/EJI Immunology Summer School 2010, Italy

Prize

  • EACR “Young Researcher Award” at the PIVAC9 conference in 2009

 Fellowships

  • Dutch Cancer Foundation (KWF) “Master student fellowship grant,” the grant was used to finance my post-graduate research project at the Academy of Sciences, Czech Republic

Grants

  • A “Curaçao young talent” grant was provided by the non-profit organisation “Fundashon bon intenshon” to finance my post-graduate research project at the Academy of Sciences, Czech Republic.
  1. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter for immune activation. Vaccine. 2015 (IF = 3.6)
  2. CD40-targeted Dendritic Cell Delivery of PLGA-Nanoparticle vaccine induce potent anti-tumor responses. Biomaterials 2014 (IF = 8.3)
  3. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr Opin Chem Biol. 2014 (IF = 7.7)
  4. Targeting Nanoparticles to CD40, DEC-205 or CD11c Molecules on Dendritic Cells for Efficient CD8+ T cell Response: A Comparative Study. J Control Release. 2014 (IF = 7.261)
  5. Dendritic cells process long synthetic peptides better than whole protein, improving antigen presentation and T‐cell activation. Eur J Immunol. 2013. (IF = 4.5)
  6. Efficient ex vivo induction of T cells with potent anti-tumour activity by protein antigen encapsulated in nanoparticles. Cancer Immunol Immunother. 2013 (IF = 3.9)
  7. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low burst: release is crucial for efficient CD8+ T cell activation. Eur J Pharm Biopharm. 2012 (IF = 4.3)
  8. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model. Immunobiology. 2012 (IF = 3.2)
  9. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fibre-modified adenovirus-5/3. J Immunother. 2009 (IF = 3.2)
  10. Passive immunisation of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol. 2007 (IF = 3.3)
  1. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int J Oncol. 2006 (IF = 2.7)